Profile data is unavailable for this security.
About the company
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.
- Revenue in USD (TTM)0.00
- Net income in USD-6.59m
- Incorporated2018
- Employees8.00
- LocationShuttle Pharmaceuticals Holdings Inc401 Professional Drive, Suite 260GAITHERSBURG 20879United StatesUSA
- Phone+1 (240) 403-4212
- Fax+1 (845) 818-3588
- Websitehttps://shuttlepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ainos Inc | 93.68k | -14.56m | 6.66m | 46.00 | -- | 0.2872 | -- | 71.11 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.10m | 6.68m | 8.00 | -- | 0.3358 | -- | -- | -14.03 | -14.17 | 0.00 | 19.06 | 0.00 | -- | -- | 0.00 | -49.97 | -- | -53.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| TFF Pharmaceuticals Inc | 885.71k | -19.93m | 6.85m | 19.00 | -- | 1.05 | -- | 7.73 | -10.20 | -10.20 | 0.4371 | 2.11 | 0.0647 | -- | 3.72 | 46,616.32 | -145.46 | -79.57 | -181.57 | -83.41 | -- | -- | -2,249.83 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -10.10m | 6.87m | 5.00 | -- | 0.553 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -12.17m | 6.88m | 3.00 | -- | -- | -- | -- | -0.3188 | -0.3188 | 0.00 | -0.2724 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| Pulmatrix Inc | 11.68m | -8.85m | 6.90m | 22.00 | -- | 0.3626 | -- | 0.5903 | -2.42 | -2.42 | 3.20 | 5.21 | 0.3517 | -- | 17.84 | 531,090.90 | -26.63 | -46.91 | -30.21 | -58.12 | -- | -- | -75.73 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.01m | 6.92m | -- | -- | 3.24 | -- | -- | -1.37 | -1.37 | 0.00 | 0.4808 | 0.00 | -- | -- | -- | -117.26 | -74.49 | -140.56 | -92.56 | -- | -- | -- | -- | -- | -11.50 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| Scorpius Holdings Inc | 2.23m | -46.05m | 6.93m | 77.00 | -- | 0.0756 | -- | 3.11 | -1.78 | -2.00 | 0.0859 | 1.39 | 0.0234 | -- | 0.6762 | 28,918.57 | -50.05 | -38.42 | -61.25 | -42.06 | 29.10 | -- | -2,136.28 | -703.02 | -- | -- | 0.2305 | -- | 202.12 | 33.24 | -23.85 | -- | 218.50 | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -6.59m | 6.97m | 8.00 | -- | 1.64 | -- | -- | -0.441 | -0.441 | 0.00 | 0.2524 | 0.00 | -- | -- | 0.00 | -90.28 | -- | -104.75 | -- | -- | -- | -- | -- | -- | -49.56 | 0.1527 | -- | -- | -- | -112.71 | -- | -- | -- |
| Longeveron Inc | 978.00k | -21.62m | 6.98m | 23.00 | -- | 0.9109 | -- | 7.14 | -9.58 | -9.58 | 0.4297 | 1.21 | 0.0621 | -- | 7.14 | 42,521.74 | -132.19 | -63.15 | -184.16 | -75.68 | 48.47 | 33.70 | -2,129.24 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Cell MedX Corp | 70.00 | -96.91k | 6.99m | 0.00 | -- | -- | -- | 99,786.50 | -0.0029 | -0.0029 | 0.00 | -0.0024 | 0.0015 | -- | -- | -- | -202.28 | -792.55 | -- | -- | -685.71 | -- | -138,442.90 | -3,681.84 | -- | -3.17 | -- | -- | -54.53 | -- | 29.01 | -- | -- | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 7.07m | 15.00 | -- | 0.3216 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 2.83m | -10.03m | 7.20m | 17.00 | -- | 0.6046 | -- | 2.55 | -64.14 | -64.14 | 4.60 | 3.82 | 0.2041 | 2.69 | 7.77 | 166,299.40 | -72.67 | -80.65 | -107.67 | -224.84 | 23.33 | -- | -356.09 | -948.54 | 1.87 | -- | 0.0451 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
| Notable Labs Ltd | 311.00k | -12.39m | 7.21m | 16.00 | -- | 0.6249 | -- | 23.20 | -2.31 | -2.31 | 0.0622 | 1.28 | 0.0142 | -- | -- | 19,437.50 | -56.70 | -52.02 | -74.10 | -62.09 | 37.30 | 60.19 | -3,984.24 | -3,636.93 | -- | -- | 0.0271 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Trevena Inc | 3.14m | -40.15m | 7.34m | 23.00 | -- | -- | -- | 2.34 | -2.71 | -2.71 | 0.2107 | -0.7999 | 0.0904 | -- | -- | 136,478.30 | -115.65 | -55.93 | -148.14 | -66.35 | 48.04 | -- | -1,279.01 | -3,134.41 | -- | -15.39 | 1.88 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Paranovus Entertainment Technology Ltd | 51.46m | -42.62m | 7.34m | 80.00 | -- | 0.6871 | -- | 0.1426 | -7.16 | -7.49 | 9.89 | 1.46 | 1.18 | 59.61 | 4.15 | 643,209.90 | -91.12 | -23.19 | -119.36 | -27.21 | 4.92 | 23.09 | -77.15 | -24.25 | 3.97 | -2,465.22 | 0.00 | -- | 9.68 | 9.80 | -45.84 | -- | -21.93 | -- |
Data as of May 24 2024. Currency figures normalised to Shuttle Pharmaceuticals Holdings Inc's reporting currency: US Dollar USD
1.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ayrton Capital LLCas of 30 Sep 2023 | 220.43k | 1.31% |
| Geode Capital Management LLCas of 31 Mar 2024 | 36.96k | 0.22% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 16.50k | 0.10% |
| Virtu Americas LLCas of 31 Mar 2024 | 10.48k | 0.06% |
| UBS Securities LLCas of 31 Mar 2024 | 1.12k | 0.01% |
| Desjardins Securities, Inc.as of 31 Mar 2024 | 500.00 | 0.00% |
| Tower Research Capital LLCas of 31 Mar 2024 | 251.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 54.00 | 0.00% |
| StoneX Group, Inc. (Investment Management)as of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
